Three well-known United States research-peptide suppliers exited the market within about a year of each other: Amino Asylum in 2025, Science.bio around January 2026, and Peptide Sciences on March 6, 2026. For labs and independent researchers, a meaningful share of the sourcing landscape changed in a short window, and anyone still relying on a supplier relationship built before 2025 should treat sourcing continuity as an active, ongoing task rather than something to revisit only after the next shutdown. This guide summarizes what happened, lays out a standard rubric for vetting any research-compound supplier, and links to dedicated transition guides for researchers coming from each of the three suppliers above.
The 2025-2026 Shutdown Timeline
Amino Asylum was the first of the three to close, ceasing operations in 2025. Science.bio followed, shutting down around January 2026. Peptide Sciences, one of the more established names in the space, closed voluntarily on March 6, 2026. None of the three closures has been publicly tied to a single common cause, and researchers should be cautious about drawing broad conclusions about the industry from any one shutdown in isolation. What the three do share is practical: each interrupted supply for researchers with active protocols, recurring orders, or lot-specific documentation tied to that supplier, and each required an unplanned sourcing transition. For dedicated coverage of each, see the guides on Peptide Sciences, Science.bio, and Amino Asylum.
Why the Supply Landscape Has Been Volatile
Research-compound suppliers operate with real logistical and compliance overhead: maintaining relationships with synthesis labs, funding independent third-party testing for every batch, and managing United States domestic fulfillment all require sustained operational investment. Not every seller in the space maintains that overhead consistently, and turnover is common even outside a defined shutdown wave. The practical implication for a researcher is not to try to predict which supplier closes next, but to build sourcing practices that are resilient to any single vendor disappearing, namely maintaining documentation discipline and being ready to requalify a new supplier quickly against an objective standard.
A Standard Rubric for Vetting Any Supplier
Regardless of which supplier closed or why a new one is being evaluated, the same four criteria apply. Independent third-party testing: every batch should be verified by a laboratory with no financial relationship to the seller, and the report should be checkable independently rather than taken on faith. Dual analytical verification: a legitimate Certificate of Analysis includes both HPLC data with a visible chromatogram establishing purity and mass spectrometry data confirming molecular identity against theoretical molecular weight; a single purity percentage with no raw data behind it is not adequate documentation. Domestic United States shipping: fulfillment from United States-based inventory shortens transit time for temperature-sensitive lyophilized material and avoids the customs uncertainty associated with international shipments.
Catalog transparency: legitimate suppliers list molecular weight, sequence or structural data, and lot numbers directly on product pages, and are willing to answer direct questions about which laboratory tested a specific lot. A supplier that fails any one of these four checks is a weaker link in a research supply chain, independent of price or catalog breadth. Ascension Labs documents all four across its full catalog, tested by Janoshik Analytical, and the Certificate of Analysis page explains how to read and independently verify the reports provided with each order.
Building a Shutdown-Resilient Sourcing Practice
Beyond vetting a single replacement supplier, labs that want to avoid repeating this scramble the next time a vendor exits should build a few habits into standard operating procedure: keep COAs on file for every batch ever used, not only the current one; periodically re-verify that an existing supplier still meets the four-point standard rather than assuming a past vetting decision holds indefinitely; and maintain awareness of at least one qualified backup supplier for compounds central to ongoing protocols. None of this requires dual-sourcing every order; it simply means the documentation and vetting work is done in advance, so a shutdown becomes a purchasing decision rather than a research delay.
Compound-Specific Guidance for Common Research Categories
For prior protocols involving growth hormone axis research, the CJC-1295 vs. Ipamorelin comparison helps confirm which secretagogue variant matches a given experimental design before reordering. For work involving tissue-repair mechanism research, the BPC-157 vs. TB-500 comparison covers the specification differences relevant to protocol selection. For the full range of categories, including neuropeptides, copper-peptide research, and metabolic compounds, the Ascension Labs catalog lists current batch-specific documentation for each product, the fastest way to confirm a replacement compound matches what a protocol requires.
Research Use Notice
Every compound referenced in this guide, and in the vendor-specific guides it links to, is sold for laboratory research use only; not for human or veterinary use. This is sourcing-continuity information for laboratories and qualified researchers, and nothing in this guide constitutes a therapeutic claim, dosing recommendation, or endorsement of use outside a controlled research setting.
Frequently Asked Questions
Are more research-peptide suppliers expected to shut down? Individual vendor closures cannot be predicted, but the 2025-2026 pattern suggests researchers should not assume any single supplier relationship is permanent, and should keep documentation and a vetting process ready regardless of which supplier is currently in use.
Is there a connection between Amino Asylum, Science.bio, and Peptide Sciences closing within a similar period? Each closure has been reported separately, and this guide does not assert a shared cause between them. The relevant fact for researchers is that all three are no longer operating and each requires a documented alternative supplier.
What is the single most important document to request from a new supplier? The batch-specific Certificate of Analysis. It should be tied to the exact lot being purchased, issued by an independent laboratory, and include both HPLC purity data and mass spectrometry identity confirmation; see the COA guide for a full walkthrough of what to check.
Does the Ascension Labs catalog cover the same compound categories as all three closed suppliers? The catalog overlaps with the categories commonly sourced from all three, namely growth hormone secretagogues, tissue-repair research peptides, neuropeptides, and metabolic research compounds, though researchers should always confirm exact specifications against the current COA rather than assuming a category match guarantees an identical product.
Where is the best place to start when sourcing from more than one of these three suppliers previously? Start with the dedicated guide for whichever supplier carried the highest-priority compounds, Peptide Sciences, Science.bio, or Amino Asylum, and apply the four-point rubric from this guide to consolidate remaining sourcing with a single, fully documented supplier where practical.